meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
versus all
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab plus endocrine therapy
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antibody–drug conjugate
trastuzumab emtasine plus endocrine therapy
es-BC - HR positive - (neo)adjuvant (NA)
2
Comparator:
vs trastuzumab plus endocrine therapy;
Risk of bias:
low;
some concerns;
high;
NA;